Search results
Showing 76 to 90 of 173 results for leukaemia
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.
bendamustine with chlorambucil at the higher dose used in the Chronic Lymphocytic Leukaemia Trial 4 (CLL4). Any explanatory notes(if...
Find out which guidance and quality standards are awaiting development
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
View a complete list of all our guidance, NICE advice and quality standards currently in development
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.
Past technology appraisal appeals and decisions
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Discontinued Reference number: GID-TA10767
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.
View recommendations for HTG693Show all sections